Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
151 USD | -2.38% | +5.93% | +51.85% |
Jun. 08 | US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59 | RE |
Jun. 07 | Moderna Files With FDA for Updated Covid Shot | DJ |
Business Summary
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Number of employees: 5,600
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Messenger RNA (mRNA) Medicines
100.0
%
| 19,263 | 100.0 % | 6,848 | 100.0 % | -64.45% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Rest of World
52.5
%
| 7,298 | 37.9 % | 3,598 | 52.5 % | -50.70% |
United States
27.7
%
| 5,150 | 26.7 % | 1,895 | 27.7 % | -63.20% |
Europe
19.8
%
| 6,815 | 35.4 % | 1,355 | 19.8 % | -80.12% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 51 | 11-02-28 |
James Mock
DFI | Director of Finance/CFO | 47 | 22-09-05 |
Stephen Hoge
PSD | President | 48 | 12-12-31 |
Brad Miller
CTO | Chief Tech/Sci/R&D Officer | - | 23-01-02 |
Jerh Collins
CTO | Chief Tech/Sci/R&D Officer | - | 22-12-31 |
Investor Relations Contact | - | 19-03-31 | |
Jonathan Hoggatt
PRN | Corporate Officer/Principal | - | - |
José M. Vega
PRN | Corporate Officer/Principal | - | 21-01-10 |
Corporate Officer/Principal | - | 20-05-10 | |
Charbel Haber
LAW | General Counsel | - | 20-04-20 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Sagan
BRD | Director/Board Member | 65 | 18-05-31 |
Director/Board Member | 74 | 20-06-30 | |
Francois Nader
BRD | Director/Board Member | 67 | 19-12-10 |
Noubar Afeyan
FOU | Founder | 60 | 09-12-31 |
Robert Langer
FOU | Founder | 74 | 09-12-31 |
Stéphane Bancel
CEO | Chief Executive Officer | 51 | 11-02-28 |
Sandra Horning
BRD | Director/Board Member | 75 | 20-02-29 |
Elizabeth Nabel
BRD | Director/Board Member | 72 | 15-11-30 |
Stephen Berenson
BRD | Director/Board Member | 63 | 17-09-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 383,239,726 | 346,535,528 ( 90.42 %) | 0 | 90.42 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
GENERATION BIO CO. 8.81% | 5,859,375 | 8.81% | 18,632,813 $ |
METAGENOMI, INC. 4.56% | 1,707,473 | 4.56% | 10,893,678 $ |
CARISMA THERAPEUTICS, INC. 12.18% | 5,059,338 | 12.18% | 6,728,920 $ |
Company contact information
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.85% | 57.87B | |
+41.70% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B | |
-9.14% | 11.06B |
- Stock Market
- Equities
- MRNA Stock
- Company Moderna, Inc.